After doubling sales of its Biogen-partnered Alzheimer’s disease med Leqembi in its 2025 fiscal year, Eisai figures the crawl to its blockbuster ambitions will hit a stride in 2026, when it expects | ...

Cochrane review says amyloid-targeting Alzheimer's drugs are ineffective, but the Alzheimer's Association and drug makers ...

For more than 15 years, much of the Alzheimer’s Disease establishment has focused its attention—and hundreds of millions of research dollars—on the theory that the disease primarily is caused by the ...

Drugs designed to clear amyloid beta from the brain—once seen as a promising path to slowing Alzheimer’s—may not actually ...

For years, the great hope in Alzheimer’s research has been that if scientists could clear the brain of Alzheimer’s physical ...

St. Jude researchers revealed that midkine blocks amyloid beta from forming harmful clumps linked to Alzheimer’s. Without it, the damaging assemblies accelerate, but with it, growth halts. The finding ...

Acumen Pharmaceuticals (NASDAQ:ABOS) said its Phase 2 ALTITUDE-AD trial of sabirnetug remains on track, with top-line results ...

Please provide your email address to receive an email when new articles are posted on . Decreased levels of plasma amyloid beta 42 at midlife, but not late life, correlated with an increased risk for ...